SECsense Logo

Anebulo Pharmaceuticals 8-K Report: Key Updates on Common Stock & Corporate Events

$ANEB
Form 8-K
Filed on: 2025-02-12
Source
Anebulo Pharmaceuticals 8-K Report: Key Updates on Common Stock & Corporate Events

Based on the provided section of the financial report, here are the key pieces of information extracted:

  1. Entity Information:
  • Name: Anebulo Pharmaceuticals, Inc.
  • CIK: 0001815974
  • SEC File Number: 001-40388
  • EIN: 85-1170950
  • Address: 1017 Ranch Road 620 South, Suite 107, Lakeway, TX 78734
  • Phone: (512) 598-0931
  1. Report Type:
  • Filing: 8-K (Current Report)
  1. Filing Date:
  • Date of Report: February 11, 2025
  1. Common Stock Details:
  • Par Value: $0.001 per share
  • Ticker Symbol: ANEB
  • Exchange: NASDAQ
  1. Period Information:
  • Period Start Date: February 11, 2025
  • Period End Date: February 11, 2025
  1. Measurement Units:
  • Currency: USD
  • Share Measurement: Shares

Insights:

  • The filing indicates that Anebulo Pharmaceuticals is a publicly traded company on NASDAQ under the ticker ANEB, suggesting it is in the biotech or pharmaceutical sector.
  • The use of an 8-K report implies that this filing likely includes important corporate events or changes that could affect the company's stock price or operations.
  • The report indicates a focus on common stock, potentially signaling activities related to equity, such as new issues, stock buybacks, or other corporate actions that may impact shareholders.
  • The specific date of the report may suggest a significant event or announcement made by the company on that date.

This analysis helps stakeholders understand the basic identity of Anebulo Pharmaceuticals, the context of the report, and its implications for investors and analysts monitoring the company's performance.